Printed From BioPortfolio.com
FDA approves first adjuvant treatment to reduce risk of kidney cancer recurrence
04:22 EST 17 Nov 2017 | News-Medical.net
The U.S. Food and Drug Administration today approved Sutent (sunitinib malate) for the adjuvant treatment of adult patients who are at a high risk of kidney cancer (renal cell carcinoma) returning after a kidney has been removed (nephrectomy).
Original Article: FDA approves first adjuvant treatment to reduce risk of kidney cancer recurrence
